Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Investor Presentation (January 2023)
32 slides from Piramal Pharma's investor presentation, Jan 5, 2023
Slide 1: Exchange filing cover letter for investor presentation
05th January, 2023 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Investor Presentation under the SEBI (Listing Obligations a
Slide 2: Investor Presentation January 2023
Investor Presentation January 2023
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'pl
Slide 4: Our Purpose and Core Values
Our 1 Purpose and Core Values Our Purpose Core Values Doing Well & Doing Good Knowledge Action Care Impact Serving people Expertise Entrepreneurship Trusteeship Performance We aim to serve our customers, community, employees, partners and We protect and enhance We strive for a deeper We are empowere
Slide 5: Phases of our Evolution
Phases of our Evolution 1988 2010 2020 2022 Piramal Healthcare Piramal Enterprises Piramal Pharma Ltd. Domestic Formulations Piramal Pharma Financial Services CDMO Pharma Solutions Nicholas CDMO Wholesale Lending Laboratories Critical Care Complex Hospital Generics Complex Hospital Generics Multi-pr
Slide 6: Piramal Pharma Key Highlights
Piramal Pharma Key Highlights
Slide 7: Three-Pronged Business Model with Market Leading Positions
Three-Pronged Business Model with Market Leading Positions... Contract Development and Manufacturing Organisation (CDMO) Complex Hospital Generics (CHG) India Consumer Healthcare (ICH) 13 CDMO sites across North America, Europe and India Inhalation Anesthesia Anesthesia Ahmedabad1 Grangemouth Pitham
Slide 8: …in Attractive and Large Industry Segments
…in Attractive and Large Industry Segments CDMO Complex Hospital Generics (CHG) India Consumer Healthcare (ICH) CDMO Market Growing at a Healthy …With Robust Growth in Small Addressable market size of CHG Addressable market size of ICH Pace… Molecule CDMOs (In USD Bn) (In USD Bn)1 CAGR of 7% CAGR of
Slide 9: Global Footprint with a Diversified Revenue Base
Global Footprint with a Diversified Revenue Base 15 100+ ~500 6,000+ Manufacturing Sites Countries Countrieswith with CHG Customers CDMO Customers Commercial commercialPresence presence (Hospitals) Total FY22 Revenue by Geography Total FY22 Revenue by Segments India Consumer Other Healthcare 10% 11%
Slide 10: Best-in-Class Quality Track Record
Best-in-Class Quality Track Record 293 37 Zero ~127 total regulatory USFDA inspections OAIs1,2 Annual customer audits inspections1 successfully cleared1 Strong quality function with 1,000 people across sites and reporting directly to the Chairperson Advancement journey from 'Quality for Compliance
Slide 11: Track Record of Organic and Inorganic Expansion
Track Record of Organic and Inorganic Expansion $157 Mn of Growth Capex across Discovery, Development and Commercial Manufacturing within CDMO Healthy ROI on Organic Investments Investments to bolster capacity across key Inhalation Anesthesia products in Complex Hospital Generics Sales Promoti
Slide 12: Focus on Patient and Customer Centricity: source of differentiation
Focus on Patient and Customer Centricity: source of differentiation Focusing on Patient-centricity and Customer-centricity drives our organization to provide flexible high-quality service while aligning us with our customer partners on our shared goal of serving patients CDMO Complex Hospital Gene
Slide 13: Institutional Focus on ESG
Institutional Focus on ESG Established ESG Framework… …with Significant Impact Environment Energy Business Ethics and Management Compliance ~82K 11% Hazardous waste co-processed in Trees planted during across facilities FY22 Water Stewardship Responsible and Waste Supply Chain Management ~137K ~145K
Slide 14: CDMO
Piramal Pharma Limited
Slide 15: CDMO Segment has delivered Consistent growth over the years – FY11 to FY22
CDMO Segment has delivered Consistent growth over the years – FY11 to FY22 CDMO CHG ICH Revenue in INR Cr (FY11-FY22) Consistent Growth over the years driven by: 13% CAGR 3,960 Differentiated service offerings in areas of High 3,616 Potent API, Complex OSDs, Potent Sterile Injectables, Peptides, A
Slide 16: Service Offerings Across the Lifecycle of the Molecule
Service Offerings Across the Lifecycle of the Molecule With a High Proportion of Commercial Revenues CDMO CHG ICH Discovery Development Commercial Manufacturing Strengthened Molecule Pipeline across Clinical Phases with 3.4x Growth in Phase-III Molecules since FY17 >90% 172 50+ 65+ Pipeline of molec
Slide 17: Attracting Customers with Differentiated Offerings and Integrated Services
Attracting Customers with Differentiated Offerings and Integrated Services CDMO CHG ICH Integrating Services: Discovery - Clinical Development - Commercialization Preclinical Phase 1 Phase 2 Phase 3 Launch Off-patent Commercial CRO Development (CDMO & Generic API) Late Phase & Commercial (CDMO & Gen
Slide 18: Positioned at an inflection point with multiple growth drivers
Positioned at an inflection point with multiple growth drivers CDMO CHG ICH Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Pursue inorganic growth Customer Focus on expanding technical/product capabilities and to offer integrated Capability services to a larger customer base Sup
Slide 19: Complex Hospital Generics
Complex Hospital Generics Piramal Pharma Limited
Slide 20: Leveraging our Differentiated Portfolio for Gaining Market Share and Driving Growth
Leveraging our Differentiated Portfolio for Gaining Market Share and Driving Growth CDMO CHG ICH Differentiated Portfolio of 40 Products Spanning Inhalation Anesthesia and Injectable Inhalation Anesthesia (58%1) Injectable Anesthesia and pain management (17%1) #1 #4 in Intrathecal in Inhalation port
Slide 21: Strong Pipeline in Niche Areas with Unique Characteristics
Strong Pipeline in Niche Areas with Unique Characteristics CDMO CHG ICH Building Pipeline in Niche Areas… …By Leveraging Internal Capabilities and Key Partnerships Injectable Anesthesia Pain Management Development and manufacturing partners around the globe A broad range of other Our internal regu
Slide 22: Vertically Integrated Manufacturing Capabilities and Well Built Out Commercial Infrastructure
Vertically Integrated Manufacturing Capabilities and Well Built Out Commercial Infrastructure CDMO CHG ICH Key Starting Material Finished Products Distribution Direct Sales Vertically Integrated Manufacturing Capabilities1 with Global Regulatory Accreditations Commercial Presence through a Combinati
Slide 23: India Consumer Healthcare
India Consumer Healthcare Piramal Pharma Limited
Slide 24: Diversified Portfolio of Attractive Brands, Including Power Brands
Diversified Portfolio of Attractive Brands, Including Power Brands CDMO CHG ICH Analgesics Skin Care VMS Women’s Health Digestives Kids Wellness Health & Hygiene Lacto Calamine i-pill, i-know Littles Supradyn Contraceptive Pill, Saridon Oil Control Lotion, Multivitamin Polycrol Wipes, Toys, Headache
Slide 25: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing CDMO CHG ICH Investments in Brand Promotion and Marketing Kareena Kapoor Priyanka Mohan Sourav Ganguly Amyra Dastur Ajay Devgan i-pill Daily Little’s Lacto - South India Polycrol Lacto - HSM belt Tetmosol New Media la
Slide 26: Well Established Commercial Infrastructure with Multi-channel Distribution Strategy
Well Established Commercial Infrastructure with Multi-channel Distribution Strategy CDMO CHG ICH Wide Coverage Across General Trade, Chemist and Toy Shops Strengthening Presence in Alternate Channels Indirect Wholesale coverage Hyper + Super Markets (~8,000 wholesalers) Pharmacy Chains 9,000+ stores
Slide 27: Ophthalmology Branded Products
Ophthalmology Branded Products
Slide 28: Strategic Ophthalmology JV with a #1 Position in the Domestic Market
Strategic Ophthalmology JV with a #1 Position in the Domestic Market JV Arrangement #1 425 in Indian employees including Ownership Ownership Ophthalmology Market sales force 49% 51% Revenue1 (INR Cr.) 9% CAGR Strong 329 414 presence 30% in major disease FY22 PAT Margin 169 segments FY12 FY17 FY22 No
Slide 29: To Summarize
To Summarize Piramal Pharma Limited
Slide 30: Key Strategic Priorities
Key Strategic Priorities 1 Delivering consistent revenue growth and improving profitability 2 Pursuing organic and inorganic growth opportunities leveraging fresh capital Track record of building scalable differentiated Capacity expansion across multiple sites pharma businesses with Acquisitions
Slide 31: To Summarise
To Summarise Three Pillars of the Top 3 Top 4 Top 10 Business1 CDMO in India in Inhalation in OTC in India (Top 13 Globally) Anesthesia Globally Diversified Diversified Manufacturing Manufacturing 15 37 Nil Footprint Footprint with with Strong Manufacturing Best-in-class Quality Track Record Success
Slide 32: Thank You
Thank You Piramal Pharma Limited
Piramal Pharma — Investor Presentation (January 2023) on 6ix